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Abstract 17	  
Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus acidophilus 18	  
and Enterococcus faecium, which are the component species of a 19	  
commercially available probiotic mixture (Symprove®, P1), were grown in co-20	  
culture to determine whether they would inhibit each other in vitro using an 21	  
isothermal microcalorimeter (IMC). The growth profiles in the IMC were 22	  
characteristic and unique to each species while the growth profile of P1 was 23	  
most similar to that of L. plantarum, suggesting this is the dominant organism 24	  
in mixed-culture. Bacterial growth in the cell free supernatants (CFS) of the 25	  
probiotic species were also evaluated by IMC and viable counts determined at 26	  
the end of the incubation period. L. plantarum was found to be the most 27	  
effective species at inhibiting L. rhamnosus. Conversely, L. rhamnosus was 28	  
the most effective at limiting the growth of L. plantarum. Both L. plantarum 29	  
and L. rhamnosus were inhibitory toward L. acidophilus and E. faecium. E. 30	  
faecium was the least inhibitory towards all the other species. The study 31	  
shows how complex, multi-species probiotic products can be analysed to 32	  
determine the predominant species, and so provides a route to formulation of 33	  
new products. 34	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1. Introduction 40	  
Probiotics are defined as “live microorganisms that, when administered in 41	  
adequate amounts, confer a health effect on the host” [1]. Probiotics are 42	  
claimed to improve digestibility and nutrition [2, 3], prevent the occurrence of 43	  
diarrhoea [4], reduce cancer risk [5], prevent or alleviate allergies and atopic 44	  
diseases [6, 7] and prevent and treat infectious diseases [8]. The mechanism 45	  
by which their beneficial effects are achieved has been proposed to include 46	  
competition for nutrients, production of antimicrobial substances, competition 47	  
for adhesion receptors and stimulation of immunity [9, 10]. 48	  
Probiotics are usually members of the genera Lactobacillus and 49	  
Bifidobacterium (although some members of the genera Streptococcus, 50	  
Enterococcus, Lactococcus spp., Bacillus spp. and some yeast, for example 51	  
Saccharomyces boulardii, have been identified as probiotics). They are known 52	  
as members of the microbiota, which significantly contribute to a beneficial 53	  
health effect and have a long history of safe use [11]. Initially it was 54	  
anticipated that single probiotic strains from these genera or species could 55	  
produce the intended health benefits using the mechanisms underlined but as 56	  
knowledge of probiotic use has developed it is becoming clearer that for 57	  
optimal effect, mixed probiotics should be formulated. This resolution 58	  
stemmed from the basis that it was unlikely a single probiotic strain could 59	  
colonize the gut and achieve all therapeutic benefits and also because 60	  
probiotics could be used for targeting a number of diseases; each targeted 61	  
disease may require a specific probiotic property, which cannot be found in a 62	  
single probiotic strain [12-15]. Multi-species probiotic products are therefore 63	  
now commonly available and although some have not shown superior 64	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benefits [16, 17], there exists some evidence on their greater efficacy 65	  
compared with single strains [18-21]. For example, Chapman et al. [16] 66	  
reported insignificant differences between single probiotics and mixtures when 67	  
studying the effect of probiotics against the urinary pathogens Escherichia coli 68	  
and Enterococcus faecium. Tejero-Sarinena et al. [17] also demonstrated 69	  
better potency of inhibiton by some single probiotic species than mixtures 70	  
against enteric pathogens (Clostridium difficile and Salmonella Typhimurium). 71	  
Further, a previous study by Chapman et al. [18] demonstrated that 5 multi-72	  
species probiotic preparations had significantly greater inhibitions in 12 out of 73	  
24 cases towards C. difficile, E. coli and S. typhimurium, than 15 single-74	  
species probiotics. Apella et al. [21] and Drago et al. [20] have shown the 75	  
superior potency of mixtures than single strains in inhibiting the growth of 76	  
pathogens in co-culture.  77	  
However, very little is known about the growth behaviour of individual species 78	  
in probiotic mixtures, i.e. whether there is the possibility of inhibition or 79	  
promotion of growth [18, 19]. Also a previous evaluation of commercial 80	  
probiotic products on the UK market [22] indicated that none of the multi-81	  
species products contained all the labelled species; a reason believed to be 82	  
the likely result of inhibition amongst the species. In this study, the component 83	  
species of a commercially available probiotic mixture (Symprove, P1) were 84	  
tested against each other to determine whether some probiotic species could 85	  
inhibit the growth of others in vitro. This product was selected because it is an 86	  
aqueous suspension containing 4 probiotic species and as such is unique in 87	  
the market. 88	  
Conventionally, the in vitro assessment for inhibition would involve two main 89	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methods, although there are adaptations to these. The first is the observation 90	  
of growth of the species as whole organism co-cultures or bioproduct/species 91	  
co-culture on or within selective growth media; colony counting or 92	  
turbidimetric measurements are used to determine the degree of inhibition 93	  
[20, 21, 23, 24]. The alternative is to use diffusion assays for assessment of 94	  
inhibition [18, 23, 25]. Both of these methods are well established and have 95	  
several advantages but are labour intensive and time consuming. The plate 96	  
technique allows data acquisition in a retrospective manner, with colony-97	  
forming ability being influenced by the plating procedure and morphological 98	  
alteration during treatment. Turbidimetric measurements may also not 99	  
distinguish viable cells from dead cells, while the diffusion method may be 100	  
limited by the capacity of bioproducts to enter into and spread through the 101	  
growth medium.  102	  
The use of isothermal microcalorimetry (IMC) has been shown to circumvent 103	  
some of these limitations, offering many benefits; in particular, the 104	  
experiments are simple to set up and because there is no requirement for 105	  
optical clarity, growth of live organisms can be monitored in real time, non-106	  
destructively [26, 27]. Although successfully applied in the detection and 107	  
characterization of bacteria and other microorganisms, IMC assays are 108	  
usually done on pure cultures [27-30] and complex polymicrobial systems [31, 109	  
32] are rarely explored for detection of relative growth of two or more species. 110	  
This study aimed to explore the potential of IMC to detect the relative growth 111	  
of mixed culture of probiotic species to determine whether inhibition occurs 112	  
amongst them.  113	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2. Materials and methods 114	  
2.1. Probiotic strains and product 115	  
The probiotics used were Lactobacillus acidophilus, Lactobacillus plantarum, 116	  
Lactobacillus rhamnosus and Enterococcus faecium. The species were 117	  
obtained from the manufacturer of a commercially available combination 118	  
product (Symprove®, P1) with these constituent species in the United 119	  
Kingdom. The species were obtained as dehydrated cultures (the form in 120	  
which the species are introduced to make the final product, P1). 121	  
2.2. Growth conditions and maintenance of strains 122	  
The probiotic species were cultured overnight in de Man Rogosa Sharpe 123	  
(MRS) broth (Oxoid, Basingstoke, UK) supplemented with 0.05% w/v L-124	  
cysteine hydrochloride for 24 h at 37oC under anaerobic conditions (anaerobic 125	  
jar with AnaeroGen GasPak System; Oxoid, Basingstoke, UK). The cells were 126	  
then harvested, washed in phosphate buffered saline (PBS), resuspended in 127	  
15% (v/v) glycerol at an organism density of 108 CFU/mL and frozen in 1.8 mL 128	  
aliquots over liquid nitrogen [33]. Bacterial concentration was determined by 129	  
serial dilution and colony counting. Aliquots were stored under liquid nitrogen 130	  
until required. Prior to use, they were thawed for 3 min by immersion in a 131	  
water bath (40oC) and vortexed for a period of 1 min. 132	  
2.3. Sample preparation and microcalorimeter experiments with strains 133	  
and product  134	  
For pure culture studies, the probiotic species were each inoculated into pre-135	  
warmed Brain Heart Infusion (BHI) broth or MRS broth (Oxoid, Basingstoke, 136	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UK) supplemented with 0.05% w/v L-cysteine hydrochloride (BHIc; MRSc) (in 137	  
3 mL calorimetric glass ampoules) to give individual population densities of 138	  
106 CFU/mL. The probiotic bacteria were also inoculated into the pre-warmed 139	  
medium to give a mixed culture of the individual species at concentrations of 140	  
106 CFU/mL of each organism in the ampoules. Samples of batches of P1 141	  
were inoculated into pre-warmed BHIc or MRSc in ampoules at 1 in 100 142	  
dilutions to give a final concentration of 106 CFU/mL. The ampoules were 143	  
sealed with crimped caps, vortexed for 10 s and loaded into the intermediate 144	  
position of a Thermometric Thermal Activity Monitor 2277 (TAM 2277) (TA 145	  
Instruments Ltd., UK). The temperature of the instrument was set at 37oC (± 146	  
0.1oC). The loaded samples were allowed to equilibrate thermally at the 147	  
intermediate position for 30 min before measurement. Data were collected 148	  
every 10 s, with an amplifier range of 1000 µW using the software package, 149	  
Digitam 4.1 and analysed using Origin Pro 8.6 (Microcal Software Inc.). The 150	  
reference ampoule was loaded with 3 mL of sterile media. 151	  
2.4. Cell free supernatant and microcalorimeter experiments  152	  
The cell free supernatant (CFS) obtained from each species was tested 153	  
against the producing organism and the other species. Culture supernatants 154	  
of the probiotic species were prepared by cultivating the respective species in 155	  
broth over 48 h anaerobically using an Oxoid anaerobic jar with an 156	  
AnaeroGen GasPak System (Oxoid, Basingstoke, UK). The cells were 157	  
removed by centrifuging at 3500 g for 10 min at 4oC. The supernatant was 158	  
collected and filter-sterilized using a 0.22 µm membrane syringe filter. The 159	  
pHs of the supernatants were examined and recorded. 160	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1.5 mL of CFS obtained from the species were homogeneously mixed with 161	  
double fold concentrated medium. The probiotic species were individually 162	  
inoculated into the respective CFS-broth mixture to a population density of 106 163	  
CFU/mL and placed in the TAM. Power-time measurements were then taken. 164	  
A control experiment was done by replacing the CFS with sterile distilled 165	  
water. Colony counts of serially-diluted samples of the bacteria were done 166	  
after the TAM experiments.  167	  
3. Results and Discussion 168	  
As noted above, IMC is a technique widely used for monitoring bacterial 169	  
growth [26, 34]. The raw data from IMC are a plot of power (µW or µJs-1) as a 170	  
function of time (t). The power-time data showing growth curves of 10 batches 171	  
of P1 are shown in Figure 1. The power-time curves are complex, with peaks 172	  
and troughs representing the growth phases of the individual species in the 173	  
product [35]. The growth curves are generally reproducible but there are some 174	  
variances in the lag period, which may reflect slight differences in the 175	  
numbers of organisms loaded into the calorimeter; [36].  176	  
The power-time curves of the component species of P1 (L. plantarum, L. 177	  
rhamnosus, L. acidophilus and E. faecium), their mixed culture and a batch of 178	  
the product in BHIc are compared in Figure 2. It is apparent that the curves 179	  
are characteristic for individual species, with different onset times (increase in 180	  
power from baseline) and areas under curve (AUC, representing heat output). 181	  
It is important to note that the inoculum concentration for the species were the 182	  
same; while it would be possible to explore the effect of different inoculum 183	  
concentrations, the number of permutations and combinations would be vast. 184	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The time-lag before growth for some of the species may indicate a period of 185	  
adaptation of the species to the medium [36]. AUC also varied amongst the 186	  
species with E. faecium producing the highest heat output and L. acidophilus 187	  
the least. The maximum power attained was also higher for E. faecium 188	  
relative to the other species, which could imply that growth of E. faecium in 189	  
the medium is favoured or the species adapts to the medium more quickly 190	  
than the others. Growth of the species and P1 in MRSc, Figure 3, showed 191	  
characteristic growth curves but did not show the fastest growth of E. faecium. 192	  
This result shows the importance of media selection when carrying out these 193	  
studies and suggests that the best in-vitro:in-vitro correlation will be obtained 194	  
in biorelevant media.  195	  
The growth curve of a mixed culture of all four species in BHIc appears to be 196	  
dominated by E. faecium, in line with the observation above. However, when 197	  
the growth curves are compared, the growth curve of the product (P1) 198	  
appears to share some similarities to that of the growth curve of L. plantarum 199	  
in both BHIc and MRSc. So while it is likely E. faecium rapidly adapted and 200	  
consumed the nutrients before the other species in BHIc, in the commercial 201	  
product it could have contrarily been inhibited by the other species; colony 202	  
counting at the end of the IMC study showed lower numbers of E. faecium 203	  
relative to the other species, supporting this hypothesis. The dominance of L. 204	  
plantarum in the growth curve of the product may reflect that it is very robust 205	  
and may have survived the product manufacturing process and/or storage 206	  
better relative to the other species or may have inhibited the other species 207	  
during growth. Notably, isolation and characterization of the species in the 208	  
product showed L. plantarum to be the numerically superior organism 209	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between those isolated (L. plantarum and L. rhamnosus; [22]). Also, the 210	  
power-time data of the species in the CFS of each other (Figure 4) and the 211	  
plate count data at the end of the IMC-CFS experiment (Table 1) showed that 212	  
both L. acidophilus and E. faecium did not grow in the CFS of L. plantarum 213	  
and L. rhamnosus indicating inhibition of the former organisms by the other 214	  
two probiotic species. Also, lower concentrations of viable cells (104-105 215	  
CFU/mL) were observed at the end of the IMC-CFS experiment with these 216	  
species relative to 107 CFU/mL for the others. It could be reasoned that the 217	  
CFS of L. plantarum and L. rhamnosus caused some cell death in L. 218	  
acidophilus and E. faecium.  219	  
According to the IMC data and plate count data, the CFS of L. plantarum was 220	  
the most inhibitory towards all the other species; that of E. faecium was the 221	  
least inhibitory. The CFS of L. rhamnosus was the most effective against L. 222	  
plantarum and had a greater capacity to inhibit other species than L. 223	  
acidophilus. The data also showed that the species were inhibited by their 224	  
own CFS, this being more profound in the case of L. acidophilus which had 225	  
lower final concentration of 106 CFU/mL unlike the other species, which 226	  
maintained cell count of 107 CFU/mL after incubation in their own CFS.  227	  
In this study, our goal was to explore the potential of IMC to determine 228	  
whether some probiotics could inhibit others in vitro. The data show that some 229	  
species inhibit others and therefore may consequently inhibit them when 230	  
blended together as a formulation. This observation is consistent with 231	  
previous findings of Be'er et al. [37] and Chapman et al. [18] who reported 232	  
inhibition of closely related strains and species/genera respectively. For 233	  
instance, Be'er et al. [37] reported mutual inhibition of sibling colonies of 234	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Paenibacillus dendritiformis, observing that growth inhibition and cell death 235	  
occurred if material extracted from the agar plate between the two growing 236	  
colonies was introduced near a growing single colony [37]. Also, Chapman et 237	  
al. [18] reported that among lactobacilli, bifidobacteria, Streptococcus, 238	  
Lactococcus and Bacillus species tested, mutual inhibition was observed; 239	  
however the degree of inhibition was reported to be genus-specific.  240	  
Lactobacilli were reported to be most effective in inhibiting species of other 241	  
genera followed, by bifidobacteria. Bacillus, Streptococcus and Lactococcus 242	  
species showed little ability to inhibit species from the other genera. Testing 243	  
against strains of their own genus, they also reported that lactobacilli showed 244	  
mutual inhibition amongst the species [18], which is consistent with the 245	  
present findings. The inhibitory properties of lactobacilli may be due to the 246	  
production of acids and other metabolites to which they themselves are 247	  
susceptible. According to the present study, amongst the lactobacilli tested, L. 248	  
plantarum had the greatest capacity to inhibit other bacteria followed by L. 249	  
rhamnosus then L. acidophilus. The reason for the greater inhibitory profile of 250	  
L. plantarum could be either the production of greater quantity of antimicrobial 251	  
substances or a broader spectrum of activity of the antimicrobial substances 252	  
produced. Indeed CFS produced by L. plantarum recorded the lowest pH 253	  
indicating that it may have produced the highest quantity of acidic metabolites, 254	  
which may have contributed to its inhibitory profile. 255	  
The results from the study have several implications, not least of which is the 256	  
importance for research into intra and interspecies interaction of potential 257	  
probiotic strains and species and the need for their characterization before 258	  
they are put together as a product, submissions also echoed by Myllyluoma et 259	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al. [38] when studying the effects of multispecies probiotic combinations on 260	  
Helicobacter pylori infection in vitro and Grandy et al. [39] when studying two 261	  
different probiotic preparations for treatment of acute rotavirus diarrhoea [38, 262	  
39]. One likely consequence of species inhibition in combination products is 263	  
the probability that the species inhibited is the species offering the specific 264	  
activity anticipated. Also, species may adversely react or the presence of a 265	  
species could affect the potency of the other [18, 40].  266	  
In conclusion, the results from this study show that some probiotic species 267	  
could be inhibitory to others and highlight the importance of characterizing 268	  
probiotic species before putting them together as combination products.  269	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Figure 4. Power-time data of the species in the CFS of each other; the 401	  
species in the CFS of [A], L. plantarum, [B], L. rhamnosus, [C], L. acidophilus, 402	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Table 1. Cell count of L. plantarum, L. rhamnosus, L. acidophilus and E. 405	  
faecium after incubation in the CFSs of each other (n=3). 406	  
CFS of 
species 
Cell count (log CFU/mL) of species post CFS incubation 
L. plantarum L. rhamnosus L. acidophilus E. faecium 
 L. plantarum 7.28 ± 0.07 7.09 ± 0.04 5.30 ± 0.02 4.54 ± 0.03 
L. rhamnosus 7.20 ± 0.05   7.26 ± 0.10 5.53 ± 0.06 5.36 ± 0.06 
 L. acidophilus 7.27 ± 0.13 7.38 ± 0.05 6.49 ± 0.03 7.08 ± 0.04 
 E. faecium 7.99 ± 0.03 7.58 ± 0.02 7.54 ± 0.07 7.34 ± 0.05 
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